Inhibition of MEK confers hypersensitivity to X‐radiation in the context of BRAF mutation in a model of childhood astrocytoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1545-5017|62|10|1768-1774

ISSN： 1545-5009

Source： PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol.62, Iss.10, 2015-10, pp. : 1768-1774

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhibition of MDM2 by RG7388 confers hypersensitivity to X‐radiation in xenograft models of childhood sarcoma

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 8, 2015-08 ,pp. : 1345-1352

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care

By  

Oncology, Vol. 93, Iss. 3, 2017-06 ,pp. : 164-176

Karger

Access to resources Recommend Favorite

Efficacy of the MEK inhibitor cobimetinib for wild‐type BRAF Erdheim‐Chester disease

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 1, 2018-01 ,pp. : 150-153

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinicopathologic features associated with efficacy and long‐term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors

By  

CANCER, Vol. 121, Iss. 21, 2015-11 ,pp. : 3826-3835

John Wiley & Sons Inc

Access to resources Recommend Favorite

Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 65, Iss. 3, 2018-03 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite